Stephanie Yao - Bicycle Therapeutics Senior Communications
| BCYC Stock | USD 20.54 0.28 1.38% |
Executive
Stephanie Yao is Senior Communications of Bicycle Therapeutics
| Address | Portway Building, Cambridge, United Kingdom, CB21 6GS |
| Phone | 44 1223 261 503 |
| Web | https://www.bicycletherapeutics.com |
Bicycle Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1502) % which means that it has lost $0.1502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2667) %, meaning that it created substantial loss on money invested by shareholders. Bicycle Therapeutics' management efficiency ratios could be used to measure how well Bicycle Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Bicycle Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 10.2 M, whereas Non Current Assets Total are forecasted to decline to about 18 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| JD Esq | Ideaya Biosciences | 52 | |
| Andrew MD | Merus BV | 58 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Cedrik MD | immatics biotechnologies GmbH | 48 | |
| Benjamin Stone | AnaptysBio | N/A | |
| David MBA | Inhibrx | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Beth Mueller | AnaptysBio | N/A | |
| Edna Maneval | Oric Pharmaceuticals | 64 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Angus Sinclair | IGM Biosciences | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Mr MBA | C4 Therapeutics | 46 | |
| Robert JD | MeiraGTx Holdings PLC | 48 | |
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Andres CPA | Ideaya Biosciences | 38 | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.15 |
Bicycle Therapeutics Leadership Team
Elected by the shareholders, the Bicycle Therapeutics' board of directors comprises two types of representatives: Bicycle Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bicycle. The board's role is to monitor Bicycle Therapeutics' management team and ensure that shareholders' interests are well served. Bicycle Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bicycle Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MBA, CEO Director | ||
| CBE FMedsci, NonEx CoFounder | ||
| Christian Heinis, Scientific Founder | ||
| Stephanie Yao, Senior Communications | ||
| Alistair Milnes, Chief Officer | ||
| Gillian Langford, Head Management | ||
| Lee MBA, President | ||
| Alethia Young, Chief Officer | ||
| David CFA, Senior Communications | ||
| Nicholas Keen, Chief Officer | ||
| Dr B, Chief Officer | ||
| Zafar Qadir, General Counsel | ||
| MBA MBA, Pres CFO | ||
| Travis Thompson, Chief VP | ||
| Santiago MD, Chief Officer |
Bicycle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bicycle Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.15 | ||||
| Operating Margin | (23.86) % | ||||
| Current Valuation | 526 M | ||||
| Shares Outstanding | 47.55 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 92.37 % | ||||
| Number Of Shares Shorted | 3.27 M | ||||
| Price To Earning | (3.31) X | ||||
| Price To Book | 1.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.28) | Revenue Per Share 0.716 | Quarterly Revenue Growth (0.50) | Return On Assets (0.15) | Return On Equity (0.27) |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.